Reata Pharmaceuticals, Inc. (RETA) shares rallied 14.5% in the last trading session to close at $34.54. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock’s 7.9% loss over the past four weeks.
Last month, the company reported robust financial results for the fourth quarter and full year of 2021. This might have been driving the share price rally.
This company is expected to post quarterly loss of $2.26 per share in its upcoming report, which represents a year-over-year change of -21.5%. Revenues are expected to be $1.91 million, up 103.5% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Reata Pharmaceuticals, Inc., the consensus EPS estimate for the quarter has been revised 2.3% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn’t usually translate into price appreciation. So, make sure to keep an eye on RETA going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see
the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here >>>>
Reata Pharmaceuticals, Inc. is part of the Zacks Medical – Biomedical and Genetics industry. NeoGenomics (NEO), another stock in the same industry, closed the last trading session 29.8% lower at $12.49. NEO has returned -16.9% in the past month.
For NeoGenomics
, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.17. This represents a change of -325% from what the company reported a year ago. NeoGenomics currently has a Zacks Rank of #3 (Hold).
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2022?
From inception in 2012 through 2021, the
Zacks Top 10 Stocks
portfolios gained an impressive +1,001.2% versus the S&P 500’s +348.7%. Now our Director of Research has combed through 4,000 companies covered by the Zacks Rank and has handpicked the best 10 tickers to buy and hold. Don’t miss your chance to get in…because the sooner you do, the more upside you stand to grab.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
